Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 114 participants.
Also called NCT03304821
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 114 participants
- Registry
-
NCT03304821
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03304821. Randomized; double masking; primary purpose treatment. Start 2017-12-19 (actual); primary completion 2025-07-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
- Acronym
- GPAD-3
- Condition
- Peripheral Artery Disease (PAD)
- Intervention (Drug)
- GM-CSF
- Intervention (Drug)
- Placebo
- Lead sponsor
- Emory University
- Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)
Record details
- Record id
cardio:ct-nct03304821- Content hash
b5e2714f8ff9383605e2a70148e2188d9e5e82fc15f5436d586c7448232fa4f0